We are excited to share a glimpse into our latest innovation – OncoSieve™, a next-generation diagnostic platform designed to bring accurate, accessible, and affordable cancer detection to the point of care.
OncoSieve™ combines advanced sample processing techniques with proprietary image analysis and AI-based classification to detect rare cellular and molecular signatures associated with various cancers. Our system is engineered to operate with minimal sample volumes and requires no complex laboratory infrastructure, making it ideally suited for community clinics, regional hospitals, and mobile screening programs.
The goal is simple: detect cancer earlier, more efficiently, and in more places than ever before.
What makes OncoSieve™ unique is its focus on equity and scale – a solution tailored not just for high-end facilities, but for broad deployment across underserved regions where traditional diagnostics are out of reach.
We’ve partnered with leading research institutions, clinicians, and engineers to develop a system that is fast, low-cost, and clinically meaningful. While we’re unable to share specific technical details at this time, we can assure you that OncoSieve™ is built on a strong foundation of validated science, design-for-manufacturing principles, and regulatory readiness.
Stay tuned as we prepare for pilot deployments and early clinical collaborations. OncoSieve™ is more than a device — it’s a movement towards democratized cancer detection.
If you are a healthcare provider, researcher, or potential collaborator interested in learning more, please contact us at [insert contact email].